Icatibant Zentiva

Icatibant acetate, the active ingredient in Icatibant Zentiva, is a bradykinin B2 receptor antagonist presented as a 30 mg/1 mL injection solution for subcutaneous use. It treats hereditary angioedema (C1‑inhibitor deficiency) by providing rapid relief of acute swelling episodes in affected patients.

GNH USA supplies Icatibant Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant Zentiva is indicated for hereditary angioedema, a disorder characterized by bradykinin‑mediated swelling.

Hereditary angioedema type I: rapid relief of swelling during acute attacks. Hereditary angioedema type II: rapid relief of swelling during acute attacks. Hereditary angioedema in adults: reduces duration and severity of attacks.

Common Side Effects: - Injection site pain or erythema. - Headache. - Nausea. - Dizziness. - Flushing. - Fatigue.

Serious or Rare Side Effects: - Severe hypersensitivity reactions, including anaphylaxis. - Thrombocytopenia. - Severe hypotension. - Acute pulmonary edema. - Cardiovascular collapse. - Life‑threatening angioedema unrelated to HAE.

Before using Icatibant Zentiva, consider the following precautions: - Pregnancy: safety not established; avoid unless clearly needed. - Breastfeeding: unknown excretion; weigh benefits against potential risks. - Renal impairment: monitor for accumulation, adjust if necessary. - Concomitant ACE inhibitor therapy: increased risk of angioedema; evaluate alternatives. - Known hypersensitivity to icatibant or formulation components: do not administer. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medicines that influence bradykinin pathways or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may increase risk of angioedema; avoid concurrent use. - C1‑inhibitor concentrate: simultaneous administration offers no added benefit; avoid.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may affect attack frequency; monitor clinical response. - Diuretics: may alter fluid balance; observe for hypotension. - Other subcutaneous injections at the same site: may affect absorption; rotate injection sites.